81 related articles for article (PubMed ID: 35099128)
21. Elevated microsatellite instability at selected tetranucleotide (EMAST) repeats in gastric cancer: a distinct microsatellite instability type with potential clinical impact?
Herz AL; Wisser S; Kohlruss M; Slotta-Huspenina J; Jesinghaus M; Grosser B; Steiger K; Novotny A; Hapfelmeier A; Schmidt T; Gaida MM; Weichert W; Keller G
J Pathol Clin Res; 2022 May; 8(3):233-244. PubMed ID: 35099128
[TBL] [Abstract][Full Text] [Related]
22. EMAST Type of Microsatellite Instability-A Distinct Entity or Blurred Overlap between Stable and MSI Tumors.
Vuković Đerfi K; Salar A; Cacev T; Kapitanović S
Genes (Basel); 2023 Jul; 14(7):. PubMed ID: 37510378
[TBL] [Abstract][Full Text] [Related]
23. Microsatellite instability at tetranucleotide repeats in sporadic colorectal cancer in Japan.
Yamada K; Kanazawa S; Koike J; Sugiyama H; Xu C; Funahashi K; Boland CR; Koi M; Hemmi H
Oncol Rep; 2010 Feb; 23(2):551-61. PubMed ID: 20043121
[TBL] [Abstract][Full Text] [Related]
24. Sexual Difference Matters: Females with High Microsatellite Instability Show Increased Survival after Neoadjuvant Chemotherapy in Gastric Cancer.
Kohlruss M; Ott K; Grosser B; Jesinghaus M; Slotta-Huspenina J; Novotny A; Hapfelmeier A; Schmidt T; Gaida MM; Weichert W; Keller G
Cancers (Basel); 2021 Mar; 13(5):. PubMed ID: 33801374
[TBL] [Abstract][Full Text] [Related]
25. Microsatellite instability in Gastric Cancer: Between lights and shadows.
Puliga E; Corso S; Pietrantonio F; Giordano S
Cancer Treat Rev; 2021 Apr; 95():102175. PubMed ID: 33721595
[TBL] [Abstract][Full Text] [Related]
26. No evidence of EMAST in whole genome sequencing data from 248 colorectal cancers.
Kondelin J; Martin S; Katainen R; Renkonen-Sinisalo L; Lepistö A; Koskensalo S; Böhm J; Mecklin JP; Cajuso T; Hänninen UA; Välimäki N; Ravantti J; Rajamäki K; Palin K; Aaltonen LA
Genes Chromosomes Cancer; 2021 Jul; 60(7):463-473. PubMed ID: 33527622
[TBL] [Abstract][Full Text] [Related]
27. Is elevated microsatellite alterations at selected tetranucleotide repeats (EMAST)-negative/MSI-high colorectal cancer a distinct subtype of the disease?
Park Y; Kim DW; Hong YJ; Park KU; Nam SK; Na HY; Lee HS; Kim MH; Oh HK; Kang SB
J Surg Oncol; 2020 Dec; 122(7):1462-1469. PubMed ID: 32779222
[TBL] [Abstract][Full Text] [Related]
28. Impact of Tumor Localization and Molecular Subtypes on the Prognostic and Predictive Significance of p53 Expression in Gastric Cancer.
Grosser B; Kohlruss M; Slotta-Huspenina J; Jesinghaus M; Pfarr N; Steiger K; Novotny A; Gaida MM; Schmidt T; Hapfelmeier A; Ott K; Weichert W; Keller G
Cancers (Basel); 2020 Jun; 12(6):. PubMed ID: 32630478
[TBL] [Abstract][Full Text] [Related]
29. Instability of Non-Standard Microsatellites in Relation to Prognosis in Metastatic Colorectal Cancer Patients.
Pirini F; Pasini L; Tedaldi G; Scarpi E; Marisi G; Molinari C; Calistri D; Passardi A; Ulivi P
Int J Mol Sci; 2020 May; 21(10):. PubMed ID: 32429465
[TBL] [Abstract][Full Text] [Related]
30. Prevalence of PD-L1 expression is associated with EMAST, density of peritumoral T-cells and recurrence-free survival in operable non-metastatic colorectal cancer.
Watson MM; Lea D; Gudlaugsson E; Skaland I; Hagland HR; Søreide K
Cancer Immunol Immunother; 2020 Aug; 69(8):1627-1637. PubMed ID: 32314040
[TBL] [Abstract][Full Text] [Related]
31. The Clinicopathological Features and Genetic Mutations in Gastric Cancer Patients According to EMAST and MSI Status.
Fang WL; Chen MH; Huang KH; Chang SC; Lin CH; Chao Y; Lo SS; Li AF; Wu CW; Shyr YM
Cancers (Basel); 2020 Feb; 12(3):. PubMed ID: 32120855
[No Abstract] [Full Text] [Related]
32. Elevated Microsatellite Alterations at Selected Tetranucleotides (EMAST) in Colorectal Cancer is Associated with an Elderly, Frail Phenotype and Improved Recurrence-Free Survival.
Watson MM; Kanani A; Lea D; Khajavi RB; Søreide JA; Kørner H; Hagland HR; Søreide K
Ann Surg Oncol; 2020 Apr; 27(4):1058-1067. PubMed ID: 31686344
[TBL] [Abstract][Full Text] [Related]
33. Elevated Microsatellite Alterations at Selected Tetranucleotides (EMAST) Is Not Attributed to MSH3 Loss in Stage I-III Colon cancer: An Automated, Digitalized Assessment by Immunohistochemistry of Whole Slides and Hot Spots.
Watson MM; Lea D; Hagland HR; Søreide K
Transl Oncol; 2019 Dec; 12(12):1583-1588. PubMed ID: 31677491
[TBL] [Abstract][Full Text] [Related]
34. EMAST status as a beneficial predictor of fluorouracil-based adjuvant chemotherapy for Stage II/III colorectal cancer.
Mohammadpour S; Goodarzi HR; Jafarinia M; Porhoseingholi MA; Nazemalhosseini-Mojarad E
J Cell Physiol; 2020 Apr; 235(4):3604-3611. PubMed ID: 31549400
[TBL] [Abstract][Full Text] [Related]
35. Combined Microsatellite Instability and Elevated Microsatellite Alterations at Selected Tetranucleotide Repeats (EMAST) Might Be a More Promising Immune Biomarker in Colorectal Cancer.
Chen MH; Chang SC; Lin PC; Yang SH; Lin CC; Lan YT; Lin HH; Lin CH; Lai JI; Liang WY; Lu ML; Yang MH; Chao Y
Oncologist; 2019 Dec; 24(12):1534-1542. PubMed ID: 31292272
[TBL] [Abstract][Full Text] [Related]
36. Prognostic implication of molecular subtypes and response to neoadjuvant chemotherapy in 760 gastric carcinomas: role of Epstein-Barr virus infection and high- and low-microsatellite instability.
Kohlruss M; Grosser B; Krenauer M; Slotta-Huspenina J; Jesinghaus M; Blank S; Novotny A; Reiche M; Schmidt T; Ismani L; Hapfelmeier A; Mathias D; Meyer P; Gaida MM; Bauer L; Ott K; Weichert W; Keller G
J Pathol Clin Res; 2019 Oct; 5(4):227-239. PubMed ID: 31206244
[TBL] [Abstract][Full Text] [Related]
37. MSI-L/EMAST is a predictive biomarker for metastasis in colorectal cancer patients.
Torshizi Esfahani A; Seyedna SY; Nazemalhosseini Mojarad E; Majd A; Asadzadeh Aghdaei H
J Cell Physiol; 2019 Aug; 234(8):13128-13136. PubMed ID: 30549036
[TBL] [Abstract][Full Text] [Related]
38.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
